DE60321027D1 - DIAGNOSTIC PANEL IBD-FIRST CHEK FOR ESSENTIAL DARMER DISEASE (IBD) AND IRRITATION - Google Patents

DIAGNOSTIC PANEL IBD-FIRST CHEK FOR ESSENTIAL DARMER DISEASE (IBD) AND IRRITATION

Info

Publication number
DE60321027D1
DE60321027D1 DE60321027T DE60321027T DE60321027D1 DE 60321027 D1 DE60321027 D1 DE 60321027D1 DE 60321027 T DE60321027 T DE 60321027T DE 60321027 T DE60321027 T DE 60321027T DE 60321027 D1 DE60321027 D1 DE 60321027D1
Authority
DE
Germany
Prior art keywords
ibd
disease
crohn
ulcerative colitis
lactoferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321027T
Other languages
German (de)
Inventor
James Hunter Boone
David Maxwell Lyerly
Tracy Dale Wilkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Techlab Inc
Original Assignee
Techlab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techlab Inc filed Critical Techlab Inc
Application granted granted Critical
Publication of DE60321027D1 publication Critical patent/DE60321027D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/395—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Saccharomyces
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method for the differentiation of inflammatory bowel disease (IBD) from irritable bowel disease (IBS) followed by distinguishing ulcerative colitis and Crohn's disease from other gastrointestinal illnesses. This highly differential method first uses the presence of elevated lactoferrin as a marker of intestinal inflammation to differentiate IBD from IBS. Patients suspected of IBD are then analyzed for fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as an indicator of Crohn's disease and fecal anti-neutrophil cytoplasmic antibodies (ANCA) as an indicator of ulcerative colitis. IBD patients are further monitored for intestinal inflammation using fecal lactoferrin to evaluate the effectiveness of medical therapy and to predict relapse. The apparatus comprises either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous lactoferrin, ASCA and ANCA in human feces. The method and apparatus can be used by healthcare providers to identify IBD and distinguish ulcerative colitis from Crohn's disease.
DE60321027T 2002-10-25 2003-10-24 DIAGNOSTIC PANEL IBD-FIRST CHEK FOR ESSENTIAL DARMER DISEASE (IBD) AND IRRITATION Expired - Lifetime DE60321027D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42139502P 2002-10-25 2002-10-25
PCT/US2003/034094 WO2004037073A2 (en) 2002-10-25 2003-10-24 Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel

Publications (1)

Publication Number Publication Date
DE60321027D1 true DE60321027D1 (en) 2008-06-26

Family

ID=32176708

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321027T Expired - Lifetime DE60321027D1 (en) 2002-10-25 2003-10-24 DIAGNOSTIC PANEL IBD-FIRST CHEK FOR ESSENTIAL DARMER DISEASE (IBD) AND IRRITATION

Country Status (8)

Country Link
US (1) US7785818B2 (en)
EP (1) EP1554580B1 (en)
AT (1) ATE395596T1 (en)
AU (1) AU2003284187B2 (en)
CA (1) CA2502976C (en)
DE (1) DE60321027D1 (en)
ES (1) ES2306902T3 (en)
WO (1) WO2004037073A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379066T3 (en) * 2002-09-05 2012-04-20 Techlab, Inc. Method to distinguish ulcerative colitis from Crohn's disease by detecting the presence of fecal anti-neutrophil cytoplasmic antibodies (ANCA)
EP1554580B1 (en) * 2002-10-25 2008-05-14 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US8685741B1 (en) 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
CA2794757A1 (en) 2008-11-11 2010-05-20 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
CN102341705B (en) * 2009-03-05 2015-08-19 味之素株式会社 Crohn's disease diagnostic reagent
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
ES2509616T3 (en) 2009-06-25 2014-10-17 Nestec S.A. Diagnostic procedures for irritable bowel syndrome
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
JP5857503B2 (en) * 2010-07-29 2016-02-10 小野薬品工業株式会社 Biomarkers for stress-related diseases
SI2643344T1 (en) * 2010-11-26 2017-07-31 Evonik Roehm Gmbh Human lactoferrin derived peptide for use as an antigen masking agent
ES2530175T3 (en) 2011-02-17 2015-02-26 Nestec S.A. Tests for the detection of autoantibodies against anti-TNF drugs
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
MX352274B (en) 2011-10-21 2017-11-16 Nestec Sa Methods for improving inflammatory bowel disease diagnosis.
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
CN103575903B (en) * 2012-08-07 2016-01-20 中国检验检疫科学研究院 A kind of human lactoferrin sandwich ELISA detection kit and application thereof
EP3094973B1 (en) 2013-11-07 2020-07-29 Diagnodus Limited Biomarkers
US10513552B2 (en) * 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
CN104991067A (en) * 2014-08-20 2015-10-21 苏州和锐医药科技有限公司 Preparation method and applications of anti-ASCA antibody test paper
PL3171174T3 (en) 2015-11-20 2018-04-30 Geroa Diagnostics, S.L Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease
RU2668496C2 (en) * 2017-03-16 2018-10-01 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Method of diagnosing the severity of irritable bowel syndrome
KR20200009095A (en) * 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. How to evaluate mucosal healing in patients with Crohn's disease
CN111896749A (en) * 2020-08-07 2020-11-06 杭州都林生物科技有限公司 Bovine lactoferrin double-antibody sandwich colloidal gold immunochromatographic test strip, preparation method, kit and detection method

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124252A (en) * 1989-11-28 1992-06-23 University Of Virginia Alumni Patents Foundation In vitro test for fecal leukocytes
AU1870392A (en) * 1991-03-22 1992-10-21 Valter Araujo In vitro test for leukocytes in body fluids
US6008327A (en) 1992-03-13 1999-12-28 Akzo Nobel, N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
US5359038A (en) 1992-07-14 1994-10-25 Eloy Padron Method for isolating immunoglobulin compounds in the feces
US5552292A (en) * 1993-01-18 1996-09-03 Ikagaku Co., Ltd. Method of screening for colorectal cancer
EP0615129B1 (en) 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
DE4402065A1 (en) * 1994-01-25 1995-09-07 Behringwerke Ag Saccharomyces specific antigens and antibodies, their production and use
US5681699A (en) 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5916748A (en) 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US5932429A (en) * 1996-04-12 1999-08-03 Cedars-Sinai Medical Center Methods of diagnosing clinical subtypes of crohn's disease
US5874233A (en) 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6174664B1 (en) 1997-02-05 2001-01-16 University Of Pittsburgh Screening method for inflammatory diseases using neutrophil defensins and lactoferrin
US5968741A (en) 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6727073B1 (en) * 1999-11-19 2004-04-27 Binax, Inc. Method for detecting enteric disease
US6667160B2 (en) * 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
AU2002220029B2 (en) 2000-11-14 2007-09-06 Techlab, Inc. Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker
US6818181B2 (en) 2001-03-15 2004-11-16 Savyon Diagnostics Ltd. Kit and method for detecting food allergies
US6872540B2 (en) * 2001-10-26 2005-03-29 Techlab, Inc. Method and apparatus for distinguishing Crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to Saccharomyces cerevisiae
ES2379066T3 (en) * 2002-09-05 2012-04-20 Techlab, Inc. Method to distinguish ulcerative colitis from Crohn's disease by detecting the presence of fecal anti-neutrophil cytoplasmic antibodies (ANCA)
EP1554580B1 (en) * 2002-10-25 2008-05-14 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome

Also Published As

Publication number Publication date
EP1554580A4 (en) 2006-05-31
EP1554580B1 (en) 2008-05-14
CA2502976A1 (en) 2004-05-06
WO2004037073A2 (en) 2004-05-06
WO2004037073A3 (en) 2004-07-01
CA2502976C (en) 2012-05-22
AU2003284187B2 (en) 2009-10-01
US20040137536A1 (en) 2004-07-15
US7785818B2 (en) 2010-08-31
AU2003284187A1 (en) 2004-05-13
EP1554580A2 (en) 2005-07-20
ATE395596T1 (en) 2008-05-15
ES2306902T3 (en) 2008-11-16

Similar Documents

Publication Publication Date Title
DE60321027D1 (en) DIAGNOSTIC PANEL IBD-FIRST CHEK FOR ESSENTIAL DARMER DISEASE (IBD) AND IRRITATION
Zellweger et al. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB)
Jhung et al. Toxinotype V Clostridium difficile in humans and food animals
Kane et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation
Nielsen et al. High incidence of Campylobacter concisus in gastroenteritis in North Jutland, Denmark: a population-based study
IL171020A (en) Methods for diagnosing or predicting susceptibility to types of crohn's disease
Miwanda et al. Antimicrobial drug resistance of Vibrio cholerae, Democratic Republic of the Congo
Zhou et al. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China
EP1444519A4 (en) Method and apparatus for distinguishing crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to saccharomyces cerevisiae
Miraglia A review of the centers for disease control and prevention’s guidelines for the clinical laboratory diagnosis of lyme disease
Lee et al. Prevalence of diarrhea caused by Cryptosporidium parvum in non-HIV patients in Jeollanam-do, Korea
Hyvönen et al. High prevalence of neurological sequelae and multiple chemical sensitivity among occupants of a Finnish police station damaged by dampness microbiota
Gong et al. Dimethylacetamide-induced occupational toxic hepatitis with a short term recurrence: a rare case report
Landolfi et al. Comparison of systemic cytokine levels in Mycobacterium spp. seropositive and seronegative Asian elephants (Elephas maximus)
DeMers et al. Detection and quantification of the capsular polysaccharide of Burkholderia pseudomallei in serum and urine samples from melioidosis patients
Xu et al. Pet ownership in utero and in childhood decreases the effects of environmental tobacco smoke exposure on hypertension in children: A large population based cohort study
Darton et al. Assessment and translation of the antibody-in-lymphocyte supernatant (ALS) assay to improve the diagnosis of enteric fever in two controlled human infection models and an endemic area of Nepal
Bland The gut mucosal firewall and functional medicine
Gungor et al. Effects of Helicobacter pylori infection on serology and intestinal mucosal changes in pediatric patients with celiac disease: A retrospective cohort study
Kim et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course
WO2004022713A3 (en) Method for distinguishing ulcerative colitis from crohn's disease by detecting the presence of fecal anti-neutrophil cytoplasmic antibodies (anca)
Simonsen et al. Characterization of the extent of a large outbreak of Legionnaires’ disease by serological assays
Garg et al. Unmodified Gold Nanoparticles as Diagnostic Agents for Colorimetric Detection of Mycobacterium leprae Infection
Georoff et al. Use of a Mycobacterium tuberculosis rapid lateral flow test for assessment of non-specific tuberculin responses in silvered langurs (Trachypithecus cristatus ultima)
Choe et al. Higher seroprevalence of Helicobacter pylori infection in Korean adolescent athletes compared to age‐and sex‐matched non‐athletes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MURGITROYD & COMPANY, 48149 MUENSTER